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Background: The reportedly broad expression of CD85j across different immune cell types suggests an importance
for this molecule in the human immune system. Previous reports have shown that this receptor interacts with
several HLA class-I molecules, as well as with some viral proteins. We have demonstrated that the subset of
CD85j + Natural Killer (NK) cells efficiently controls human immunodeficiency virus type 1 (HIV-1) replication in
monocyte-derived dendritic cells (MDDC) in vitro and this led us to hypothesize that the CD85j + NK cell-mediated
anti-HIV activity in MDDC is specifically dependent on the interaction between the CD85j receptor and unknown
non-HLA class-I ligand(s).
Results: In this study, we focused our efforts on the identification of these non-described ligands for CD85j. We
found that the CD85j receptor interacts with a calcium-binding proteins of the S100 family; namely, S100A9. We
further demonstrated that HIV-1 infection of MDDC induces a modulation of S100A9 expression on surface of the
MDDC, which potentially influences the anti-HIV-1 activity of human NK cells through a mechanism involving CD85j
ligation. Additionally, we showed that stimulation of NK cells with exogenous S100A9 enhances the control of HIV-1
infection in CD4+ T cells.
Conclusions: Our data show that S100A9 protein, through ligation with CD85j, can stimulate the anti-HIV-1 activity
of NK cells.
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Human leukocyte immunoglobulin-like receptors (LILRs),
also referred as immunoglobulin-like transcripts (ILTs)
and leukocyte immunoglobulin-like receptors (LIRs), are a
family of innate immune receptors that recognise self-
antigens [1]. The LILRs molecular family consists of at
least 10 genes coding for proteins of the Immunoglobulin
superfamily. Some products of these genes, such as CD85j
(alternatively: LILRB1, ILT2, or LIR-1), are surface mem-
brane inhibitory receptors which reduce cellular activation
after encountering their cognate ligands [2]. CD85j is
found on 23–77% of human Natural Killer (NK) cells, on* Correspondence: daniel.scott-algara@pasteur.fr
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reproduction in any medium, provided the ora small percentage of T lymphocytes (4–20%), on most B
cells, monocytes and dendritic cells (DC) [3-5]. This broad
expression of the inhibitory CD85j across the immune
system suggests an importance for this molecule in the
control of immune activation in humans. The data of the
literature indicate that CD85j expression is associated with
diseases both where cellular immune responses are inef-
fective, such as cytomegalovirus (CMV) infection [6], and
also where an over-active cellular immune response is det-
rimental to the host [7,8].
The extracellular region of the CD85j receptor inter-
acts with several classical and non-classical HLA class-I
molecules, as well as with the viral protein UL18 from
human CMV (HCMV) [4]. It is the only reported mem-
ber of the LILR family that recognizes a non-self anti-
gen. When CD85j is engaged by specific cross-linkingLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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inhibitory signals to dendritic cells, NK cells and T lym-
phocytes [3,5,9-12]. Escape mechanisms involving CD85j
triggering have been reported, for instance, expression of
CD85j ligands such as HLA-G on tumor cells, has been
suggested to be an escape mechanism of gamma delta
T-cell antitumoral activity [13] or continuous ligation of
CD85j on DC can induce suppression of T cell responses
[14]. Also it has been reported that the CD85j–UL18
interaction is a mechanism of viral escape from the NK
cell-mediated lysis [15,16]. However, other groups have
described it as a mechanism that leads to the killing of
HCMV-infected cells by NK cells and T lymphocytes via
non-HLA-restricted targeting [17-19]. Despite our incom-
plete understanding of the CD85j-UL18 inhibitory or acti-
vating mechanisms, this interaction appears to be of
central importance in the immune response to HCMV in-
fection. We have previously shown that the CD85j + NK
cell subset control more efficiently HIV-1 replication in
monocyte-derived dendritic cells (MDDC) compared to
their CD85j- NK cell counterpart. This CD85j + NK cell
mediated anti-HIV-1 activity is dependent on cell-to-cell
contact, and on the interaction between the CD85j recep-
tor and non-HLA class-I ligand(s) expressed on MDDC
[20]. In the present study, we focused our efforts on the
identification of unknown non-HLA class-I ligands forFigure 1 Identification of CD85j ligand(s) expressed by HIV-1-infected
blocking CD85j receptors and HLA class-I ligands as described in Materials
proteins from uninfected or HIV-1-infected MDDC lysates onto the Protein
electrophoresis in non-reducing conditions and revealed by silver staining.
eluted fractions of HIV-1-infected MDDC lysates after pre-incubation with th
donor 1; lanes 5–7, donor 2). The proteins were identified as belonging to
sequencing. (B) Eluted fractions of HIV-1-infected MDDC lysates were analyze
and anti-CD85j (lane 3) mAbs. (C) CD85j-Fc fusion protein was used to captur
where HLA-I molecules were blocked, onto the Protein chip Array.CD85j. We observed that S100A9, a calcium-binding pro-
tein of the S100 family, is expressed by MDDC in response
to HIV-1 infection and is potentially implicated in the
anti-HIV-1 activity of human NK cells through the CD85j
ligation and signalisation.
Results
Identification of non-HLA class-I ligand(s) for the CD85j
receptor
We used Protein chip array technology to initially identify
novel CD85j ligands expressed by uninfected or HIV-
1-infected MDDC. To isolate non-HLA class-I ligand(s),
we performed an immunoprecipitation procedure with
recombinant CD85j-Fc proteins targeting cognate ligands,
different from HLA class-I molecules, from uninfected or
HIV-infected MDDC lysates. Thereafter, we performed an
electrophoresis in non-reducing conditions followed by
a silver staining (Figure 1A, two representative protein
profiles) and an immunoblot (Figure 1B) to visualize the
immunoprecipitated proteins. Among the different donors
tested there were differences in the expression of CD85j
cognate partners, for instance we observed 5 (Figure 1A,
Donor 1) and 2 proteins (Figure 1A, Donor 2) in the
eluted fractions of HIV-1-infected MDDC lysates. By se-
quence comparison we were able to identify 4 molecular
forms of two proteins: S100A8 and S100A9 (AdditionalMDDC. (A) MDDC were lysed at day 2 post HIV-1 infection. After
and Methods, CD85j-Fc fusion protein was used to capture and purify
chip array. Eluted proteins from the column were separated by
Lane 1, Seeblue® Plus2 Pre-Stained Standard, lanes 2–7, subsequent
e CD85j-Fc-coupled gel from two representative donors (lanes 2–4,
S100A8/A9 complex (S100A8, S100A9 and S100A8/A9) by protein
d by immunoblotting using anti-S100A9 (lane 1), anti-S100A8 (lane 2)
e and purify proteins from uninfected or HIV-1-infected MDDC lysates,
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S100A9 (14 kDa) monomers, S100A8/S100A9 hetero-
dimer (26 kDa), (S100A8)2/(S100A9) trimer (32 kDa), as
well as (S100A8/S100A9)2 tetramer (49 kDa) in the eluted
fractions of HIV-1-infected MDDC lysates (Figure 1A).
The fractions were analyzed by immunoblotting using anti-
S100A9 (lane 1), anti-S100A8 (lane 2) and anti-CD85j (lane
3) mAbs (Figure 1B). We observed a co-localization of the
bands for S100A8 and S100A9 (lane 1 and 2, respectively)
with CD85j (lane 3), therefore the higher molecular weight
band (98 kDa) may correspond to this complex.
The interaction between CD85j receptor and eluted
S100A8/A9 proteins was then verified by Protein chip array
(Figure 1C). The peaks of the S100A8 monomer (11 kDa),
S100A8/S100A9 heterodimer (26 kDa) and trimer (32 kDa)
were consistently observed in the eluted fractions of unin-
fected and HIV-1-infected MDDC lysates. By contrast, the
peak of S100A9 monomer protein (14 kDa) was only present
in eluted fractions of HIV-1-infected MDDC lysates
(Figure 1C) and not in mock-infected conditions (data not
shown). These results supported those obtained by electro-
phoresis (Figure 1A) and the immunoblot analysis (Figure 1B).
Analysis of CD85j/S100A8 and CD85j/S100A9 interactions
The CD85j/S100A9 interaction was then analysed in
comparison to CD85j/S100A8 by ELISA test (Figure 2).
The CD85j-Fc protein bound to both recombinantFigure 2 ELISA-based CD85j/S100A8 and CD85j/S100A9 binding assay
with 4 μg/mL of recombinant GST-tagged human S100A8 or S100A9 prote
protein. (B) CD85j-Fc protein well-coated microtiter plates were incubated
S100A8 or S100A9 proteins. (C) CD85j-Fc protein well-coated were incubat
of increasing amounts of soluble CD85j-Fc protein. (D) CD85j-Fc protein w
proteins in the presence of increasing concentrations of soluble NKG2D-FcS100A8 and S100A9 monomer proteins in a dose-
dependent manner (Figure 2A). We also conducted the
reverse experiment where S100A8 or S100A9 proteins at
different concentrations were titrated over immobilized
CD85j-Fc (Figure 2B); similarly, we observed a dose-
dependent interaction between the monomeric proteins
S100A8 and S100A9, and the CD85j-Fc protein, however
a better binding of S100A9 monomer to CD85j-Fc was
found. To determine the specificity of the S100A8/
CD85j and S100A9/CD85j interactions, we blocked the
binding using increasing concentration of recombinant
CD85j-Fc protein (from 1 to 6 μg/mL). As shown in
Figure 2C, increased concentrations of soluble CD85j-Fc
protein were able to clearly block the interaction of both
S100A9 protein and in a lesser extend S100A8 protein
with immobilized-CD85j-Fc. We also performed control
blocking experiments using NKG2D-Fc protein (as a
non-related control fusion protein) at different concen-
tration (ranging from 0.3 to 2.5 μg/mL). We did not ob-
serve any block of S100A8/CD85j and S100A9/CD85j
interactions regardless the NKG2D concentration used
(Figure 2D), which confirms the specificity of these in-
teractions. We then compared the interaction of S100A9
monomers and homotetramers with the CD85j fusion
protein. A higher binding capacity of S100A9 tetramers
was detected when compared to monomers (Additional
file 2: Figure S2).. (A) Anti-GST mAbs well-coated microtiter plates were incubated
ins followed by incubation with increasing amounts of CD85j-Fc
with increasing concentrations of recombinant GST-tagged human
ed with 4 μg/mL of human S100A8 or S100A9 proteins in the presence
ell-coated were incubated with 4 μg/mL of human S100A8 or S100A9
protein. Each point is the mean ± SE of 4 determinations.
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on the surface of MDDC in response to a productive
HIV-1 infection
Our previous results suggested that CD85j ligands distinct
from HLA class-I molecules are preferentially expressed
on HIV-1-infected MDDC [20]. To explore the possibility
that the expression pattern of S100A8/A9 proteins is
modulated at the surface of MDDC in response to HIV-1
infection, we monitored their expression by flow cytome-
try over time (Figure 3). The surface expression of S100A9
was increased on MDDC in response to HIV-1 infection
(Figure 3B), whereas surface expression levels of S100A8
and S100A8/S100A9 were both decreased (Figure 3A and
3C). Further analysis of the expression of S100 proteinsFigure 3 Surface expression of S100A8, S100A9, and S100A8/
S100A9 proteins on MDDC in response to HIV-1. Kinetics of the
expression of S100A8 (A), S100A9 (B) and S100A8/S100A9 complex
(C) at the surface of MDDC (solid black line) or HIV-1-infected MDDC
(dotted black line). Results of 10 independent experiments are
summarized and expressed as mean ± SE of percentage of MDDC
expressing S100A8, S100A9, or S100A8/S100A9. **p < 0.01.following HIV-1 infection showed that S100A9 expression
was increased and S100A8/S100A9 complex expression
was decreased in MDDC that do not replicate the virus,
whereas almost none of these proteins were expressed by
MDDC replicating the virus (data not shown). Addition-
ally, the HIV-1-induced decrease of S100A8 expression
was observed on both MDDC replicating or not the
virus (data not shown). Moreover, we were able to show
that these modulations in the expression of S100A8/A9
proteins are HIV-1 dose-dependant (Additional file 3:
Figure S3). These results demonstrate distinct modula-
tions of S100A8, S100A9 and S100A8/S100A9 proteins
on MDDC in response to a productive HIV-1 infection
in vitro.
S100A9 tetramer stimulation modulates NK cell functions
Following the experiments showing the interaction be-
tween CD85j and S100A9, we wanted to examine whether
or not exogenous stimulation by these proteins can influ-
ence NK cell responses (Figure 4). As it is known that
tetramers of proteins in some cases can have greater bio-
logical activity than their monomeric counterparts [21], we
studied the effect of the monomeric and homotetrameric
forms of S100A9 on the modulation of NK cell responses.
First, we tested the modulation of NK cell function after
stimulation of purified NK cells by S100A9 proteins. As
shown in Figure 4A, a clear increase of TNF-α production
was observed when NK cells were stimulated with S100A9
tetramer whereas no modulation of TNF-α production was
detected following S100A9 monomer stimulation; stimula-
tion of NK cells with either the monomeric or the tetra-
meric form of S100A9 had no impact on the production of
IFN-γ or degranulation. Additionally, we observed that the
increase in TNF-α production following stimulation of NK
cells by S100A9 tetramers can be reduced by the co-
incubation of S100A9 tetramers with soluble CD85j-Fc
prior stimulation of NK cells (Figure 4B). We next eva-
luated the ability of S100A9 monomer- and tetramer-
stimulated NK cells to recognize the HLA–deficient target
K562 cell line (Figures 4C). As expected, stimulation of
resting NK cells with K562 cells induced cytokine secretion
and an increase of CD107a surface expression (data not
shown). Pre-stimulation of NK cells by S100A9 monomers
and tetramers (Figure 4C) induced a significant increase in
TNF-α production but had no significant effect in the
production of IFN-γ and the expression of CD107a. The
increased TNF-α production can be abrogated by stimula-
tion of NK cells with S100A9 tetramers combined with
CD85j-Fc (Additional file 4: Figure S4). Importantly,
stimulation of NK cells with S100A8 alone or followed by
K562 target recognition did not modulate the production
of cytokines nor the degranulation (data not shown).
These results therefore suggest that S100A8 monomers
stimulation does not induce a modulation of NK cell
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(either its monomeric or tetrameric form) modulates the
production of TNF-α.S100A9 tetramer stimulation potentiates anti-HIV-1-
mediated NK cell activity
We have previously shown that the engagement of the NK
CD85j receptor with non-HLA class-I ligand(s) plays a
critical role in the anti-HIV-1-mediated NK cell activity
on MDDC [20]. Since S100A9 proteins modulate NK cell
activity (Figure 4), we then tested the capacity of S100A9
stimulated NK cells to control viral replication (Figure 5).
Viral replication, measured by GFP expression, was de-
creased in MDDC after 7 days of culture with NK cells
compared to MDDC cultured without NK cells (12.5% vs
27.9% HIV/GFP + MDDC, respectively, data not shown).Figure 4 Cytokine production and CD107a expression on NK cell afte
(A) Intracellular expression of TNF-α and IFN-γ and surface expression of CD
or tetramers for 4 hours at 37°C (black, grey and white bars respectively). G
(B) NK cells were stimulated with S100A9 tetrater or with an equimolar com
stimulation, CD85j-Fc and S100A9 tetramer were co-incubated for 2 hours
of increase in TNF-α expression following stimulation compared to the uns
independent experiments. (C) Expression of intracellular TNF-α and IFN-γ a
monomer or tetramers (black, grey and white bars respectively) following a
blocking experiment regarding intracellular TNF-α expression, NK cells were
tetramer. Graph shows cumulative results from 8 independent experimentsHowever, S100A9 monomer- or tetramer-stimulated NK
cells do not have a better capacity to control HIV-1 repli-
cation in MDDC than unstimulated NK cells (Figure 5A)
instead, S100A9 monomer stimulated-NK cells seem to
slightly increase HIV-1 viral replication.
We also tested the impact of the interaction CD85j/
S100A9 in the NK cell-mediated control of HIV-1 in-
fection in purified autologous CD4+ T cells by pre-
stimulating NK cells with exogenous S100A9 proteins. Of
note, S100A8 and S100A9 proteins are constitutively ex-
pressed by phagocytic myeloid cells but they are not
expressed or induced in CD4+ T cells [22]. As HIV-1 in-
fection induces a down regulation of CD4 expression, we
studied the p24 expression in CD3+ T cells as a measure
of viral replication; cells were cultured at a NK/CD4 T cell
ratio of 1:5, which is close to physiological conditions,
without any NK cell cytokine activation. Pre-stimulation ofr stimulation by S100A9 monomer and tetramer proteins.
107a on NK cells unstimulated, stimulated by S100A9 monomers
raph shows cumulative results from 7 independent experiments.
bination of CD85j-Fc + S100A9 tetramer for 4 h at 37°C. For the later
at 37°C prior stimulation of NK cells. Graph represents the percentage
timulated NK cells. Graph shows cumulative results from 4
nd surface CD107a by NK cells unstimulated, pre-stimulated by S100A9
secondary stimulation by K562 target cells for 4 h at 37°C. For the
stimulated with an equimolar combination of CD85j-Fc + S100A9
. Results are expressed as mean ± SE and p values are indicated.
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crease in the percentage of CD3+ T cells replicating the
virus (Figure 5B), at day 7 and 10 post-infection, and
this decrease was abrogated when NK cells were pre-
stimulated with a combination of S100A9 tetramers and
CD85j-Fc. Additionally, measure of p24 in the supernatant
of the co-culture showed a significant decrease in the viral
production by CD4+ T cells following their culture with
S100A9 tetramer-stimulated NK cells (Figure 5C), and this
observed decrease in the amount of p24 antigen trended
to be abrogated when NK cells were pre-incubated with a
combination of S100A9 tetramers and CD85j-Fc. Pre-
stimulation of NK cells by S100A9 monomers induced no
change in viral replication (Figure 5B and 5C); neither
S100A8 pre-stimulation had an effect in the control of
HIV-1 infection (data not shown). Taken together, these
results show that S100A9 tetramer-stimulation of NK cells
enhances the NK cell-mediated anti-HIV-1 responses.
Discussion
By using different techniques (co-immunoprecipitation,
electrophoresis, ELISA, and Protein chip array technol-
ogy), we were able to isolate and identify new MDDC-
expressed ligands for the CD85j receptor, namely S100A8
and S100A9 proteins (Figures 1 and 2). We demonstrated
that in vitro HIV-1 infection of MDDC induces a modula-
tion of S100A8, S100A9 and S100A8/S100A9 surface ex-
pression (Figure 3). Overall, our data indicate that S100A9
(but not S100A8) may influence the anti-HIV-1 activity of
human NK cells through CD85j engagement.
We showed that only S100A9 seems to directly regu-
late cytokine production (TNF-α) by NK cells and after
secondary activation by target cells (K562) through
CD85j engagement (Figure 4). To our knowledge, it has
never been described that the engagement of the inhibi-
tory receptor CD85j on peripheral NK cells could en-
hance cytokine secretion. Li C. et al. [23] reported an
increased production of pro-inflammatory cytokines in-
cluding TNF-α by decidual NK cells after cross-linking
of CD85j by monoclonal antibodies or stimulation with
HLA-G homodimer, but they did not observe these cyto-
kine production by peripheral NK cells after stimulation.
Of note, an Immunoreceptor Tyrosine-based Switch
Motif (ITSM) in the CD85j and SAP and/or EAT adap-
tors molecules may be implicated in the activating signal
observed [23]. SAP and EAT adaptors molecules are
expressed in human NK cells and induce activating sig-
nals. This finding could explain our results, by the fact
that interaction of CD85j and S100A9 proteins may in-
duce an activating signalling mediated by the ITSM
motif. It is known that small changes in the ligands for
inhibitory receptors represent a potent mechanism for
the rapid removal of dominant inhibitory signals by
changing the interaction affinity, resulting in NK cellactivation [24]. Therefore, we can hypothesize that the
specificity and the affinity of CD85j engagement with its
ligand could influence the integration of signals and de-
termine the threshold of cellular activation. However, we
cannot rule out the possibility that S100A9 also may
interact with other receptors than CD85j. The known re-
ceptors for S100A8 and S100A9 include heparin sulphate,
TLR4, carboxylated N-glycans and the Receptor for
Advanced Glycation End-products (RAGE) [22,25,26].
Our previous work suggested that NK cells use CD85j
ligand(s) other than HLA class-I molecules to inhibit HIV-1
replication in MDDC through a cytotoxic-independent
and cell-to-cell contact-dependent mechanism [20]. Here,
S100A9 tetramer-stimulated NK cells appeared to have a
better capacity to control HIV-1 infection than unstimulated
NK cells. Therefore, we speculate that NK cells stimulated
by S100A9 protein through CD85j receptor might secrete
factors at the immunological synapses with target cells
which have the capacity to suppress HIV-1 replication.
The biological functions of S100A9 proteins can be modi-
fied by their conformational variability and multimeriza-
tion. It is then possible that monomeric and tetrameric
forms of S100A9 have different abilities to signal in NK
cells through CD85j modulating the NK cell response. We
found that S100A9 homotetramer protein interacts stron-
ger with CD85j-Fc protein than S100A9 monomer protein
(Additional file 2: Figure S2), this stronger affinity may ac-
count for the higher NK cell mediated anti-HIV-1 re-
sponse observed. As S100A9 tetramers do not induce
higher activation of NK cells towards K562 target cells,
whereas they increase anti-HIV-1 activity, it is tempting to
speculate that the signalling they induce in NK cells
prompts the cells to better respond to an HIV-1 infected
cell compared to a tumor cell line. Stimulation of NK cells
with S100A9 proteins alone or followed by tumoral target
cell induces TNF-α production. However, TNF-α has been
linked to the immune activation and the enhancement of
HIV-1 infection in CD4+ T cells. In this way, TNF-α secre-
tion might not be the main way for NK cells to control
HIV-1 infection, instead other mechanisms may account
for the viral control such as the modification of the NK
cell receptor repertoire.
Previous reports have suggested that S100A9 is in-
volved in inflammation. Indeed, the first phagocytes,
which infiltrate and dominate acute inflammatory le-
sions, have been shown to express S100A9 proteins
[27-29]. In parallel, NK cells are recruited from the
blood to the site of inflammation. Thus, the interactions
between CD85j and S100A9 proteins are likely to occur
during the early phase of HIV-1 infection characterised
by excessive inflammatory responses through NK/DC
crosstalk. This may activate CD85j-expressing NK cells
(regarding their secretory function) to control HIV-1
replication in CD4+ T cells.
Figure 5 Anti-HIV-1 activity of NK cell stimulated by S100A9
monomer or tetramer proteins. MDDC or CD4+ T cells were
infected by HIV-1 and then cultured with unstimulated, S100A9
monomer- or S100A9 tetramer-stimulated NK cells (black, grey and
white bars respectively) at the ratio E/T of 1:5. (A-B) HIV-1 replication
was measured by intracellular p24 expression in MDDC and CD4+ T
cells after 7 and 10 days of culture. (A) Graph represents cumulative
results from 4 independent experiments showing the percentage of
p24+ MDDC. (B) Graph represents cumulative results from 8
independent experiments showing the percentage of p24+ CD4+ T
cells. (C) Graph represents cumulative results from 6 independent
experiments showing the amount of p24 HIV-1 antigen in the
supernatant of HIV-1-infected CD4+ T cells in culture with
unstimulated, S100A9 monomer- or S100A9 tetramer-stimulated NK
cells (black, grey and white bars respectively). For blocking
experiments, NK cells were stimulated with an equimolar
combination of CD85j-Fc + S100A9 tetramer. Results are expressed
as mean ± SE and p values are shown.
Arnold et al. Retrovirology 2013, 10:122 Page 7 of 11
http://www.retrovirology.com/content/10/1/122S100A9 and S100A8/S100A9 complexes were almost ex-
clusively expressed by p24- MDDC and were up regulated
and down regulated respectively on p24- MDDC during
the course of a productive HIV-1 infection (Figure 3,
Additional file 5: Figure S5 and data not shown). Overall, a
productive HIV-1 infection of MDDC was needed to
induce changes in the surface expressions of S100A8,
S100A9 and S100A8/S100A9 on p24-MDDC. Bystander
effects of a productive HIV-1 infection could explain the
observed modulation and may include impairment or en-
hancement of soluble factors secreted by HIV-1 infected
cells. Though neither Nef nor Vpu proteins, both of which
are able to down regulate HLA class-I molecules [30,31],
seemed to be implicated in these S100A8 and S100A9 ex-
pression modulations on MDDC in response to HIV-1 in-
fection (Additional file 5: Figure S5 and data not shown),
however, we cannot rule out an implication of other HIV-
1 proteins. It remains to be determined whether these
HIV-1-induced modulations on MDDC represent an
established host defences against HIV-1 infection.
CD85j is highly expressed on other innate cells, such
as monocytes and dendritic cells, and also on B cells,
therefore it is possible that CD85j/S100A9 interaction
plays a role in the modulation of the activity of those
cells during HIV-1 infection. Finally, our results could
have more wide implications in the response against
pathogens or cancer cells. In cancer patients, accumula-
tion of myeloid-derived suppressor cells (MDSC), which
are known to impair anti-tumour immunity (notably by
decreasing cytotoxic function of NK cells), are regulated
by S100A9 protein [32]. According to results presented
herein, the mechanism described in cancer models could
be CD85j-mediated.
Conclusion
Our results demonstrate that S100A9 protein, through
ligation with CD85j, can stimulate the anti-HIV-1 activity
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plays an important role in the NK/DC crosstalk and there-
fore could impact the establishment and the regulation of
the specific antiviral/antitumor immune response.
Methods
Ethics statement
Blood was obtained from healthy donors through the
Etablissement Français du Sang. Written informed
consent was provided by study participants and/or their
legal guardians according to French ethical laws. This
study was approved by the Committee of Clinical
Research (number 2007–23) and the Institutional Review
Board (IRB, 06966; agreement from the Office for Human
Research Protection / United States Department of Health
and Human Services) from Institut Pasteur.
Isolation of monocytes, NK and CD4+ T cells
Peripheral blood mononuclear cells (PBMC) were ob-
tained after Ficoll gradient separation. Positive selection
for CD14+ PBMC was performed using anti-CD14
microbeads, MS+/RS + columns and a MiniMACS sep-
arator (Miltenyi Biotec). MDDC were generated from
monocytes as previously described [20]. Similarly, posi-
tive selection for CD56+ and CD4 + CD14- cells were
performed using anti-CD56 and anti-CD4 microbeads
respectively (Miltenyi Biotec). CD56+ and CD4 + CD14-
cells were frozen in 90% fetal calf serum, 10% DMSO
(Sigma). After thawing, a negative selection for CD3-
CD56+ was performed using anti-CD3 microbeads
(Invitrogen). The percentage of CD3-CD56+ NK cells
and CD4+ cells in the isolated population, evaluated by
flow cytometry, was 95%. Purification of CD85j NK cell
subsets was performed as previously described [20].
HIV-1 infection of MDDC
Immature MDDC were infected with R5 strains AD8 WT
(HIV-1), HIV-1 molecular clones lacking the Nef (HIV-
1ΔVpu) or Vpu (HIV-1ΔVpu) (a gift from Dr Olivier
Schwartz lab, Paris, France) or with a recombinant GFP
HIV-1 virus (HIV-1/GFP). We used also a single-round an
HIV-1 pseudotyped virus with vesicular stomatitis virus G
protein (HIV-1ΔEnv VSV). Infections were performed
with each virus at a multiplicity of infection (moi) of 10-1
by spinoculation. MDDC were then extensively washed
and seeded into plate wells.
Lysis of MDDC and co-immunoprecipitation
HIV-1-infected or uninfected MDDC were incubated or
not with 10 μg/ml of mouse anti-HLA-class I W6/32, anti-
HLA-class G, anti-HLA-class E (Serotec), and anti-CD85j
mAbs (Beckman Coulter), followed with donkey anti-
mouse secondary reagent (Jackson Immunoresearch). All
incubations with MDDC were performed for 30 min, atroom temperature at day 1 or day 2 post HIV-1 infection.
MDDC were harvested, centrifuged, and incubated for
40 min at 4°C in 0.5% Triton X-100 (CalBiochem) lysis
buffer with protease inhibitor (Complete, Roche). After a
microcentrifugation for 15 min at 10000 g, the supernatant
were collected. Recombinant CD85j-Fc fusion protein (R&D
System) was covalently immobilized on an amine-reactive
gel column, as described by the manufacturer (ProFound
Co-imunoprecipitation kit, Thermo Scientific Pierce). Sub-
sequently, MDDC cell lysates were loaded onto the column.
After extensive washing, CD85j-Fc-bound proteins were
eluted from the column using the elution buffer and analyzed
by protein chip array, 4-12% NuPAGE revealed by Silver-
Quest SilverStaining kit (Invitrogen) or by Western Blot.
Protein chip array
The profiles of uninfected and HIV-1-infected MDDC
lysates, as well as consecutively eluted fractions, were exam-
ined by surface-enhanced laser desorption/ionization time-
of-flight mass spectrometry (SELDI-TOF-MS) Protein chip
arrays (Ciphergen Biosystems) according to the manufac-
turer’s recommendations. Briefly, a PS10 protein chip was in-
cubated with CD85j-Fc proteins at 500 μg/ml in PBS (Gibco)
at 4°C for 18 h. Residual sites were blocked by washing the
protein chip with 1 M ethanolamine, pH 8.0, for 30 min
followed by three washes of 10 min in PBS containing 0.5%
Triton X-100 (CalBiochem). Then, samples were applied on
the chip. After incubation for 2 h at room temperature, un-
bound proteins to CD85j-Fc were removed by three succes-
sive washes of 5 min each with a buffer containing 1 mM
NaCl and 5 mM HEPES (N-2-hydroxyethylpiperazine-N’-2-
ethanesulfonic acid). Chip-captured proteins were air-dried
and covered with a matrix (3,5-dimethoxy-4-hydroxycinna-
pynic acid in 50% acetonitrile and 0.5% trifluoroacetic acid),
used as an absorbent for laser energy. The ionized and
desorbed proteins were detected and their molecular masses
displayed on the proteogram as peaks. SELDI-TOF-MS
analysis was done with the Protein-Chip Biology System II
software (PBS II) and Ciphergen Peaks software.
Western blot analysis
The eluted proteins were analyzed by 4-12% NuPAGE and
transferred to Immobilon-P membranes (Millipore). After
blocking with 5% skimmed milk, the membrane were incu-
bated with mouse anti-CD85j (Beckman Coulter), anti-
human S100A8 (2H2) or S100A9 (1C10) (Tebu-bio) mAbs
followed by secondary horseradish peroxidase-goat anti-
mouse F(ab)2 Abs (R&D System). The proteins were re-
vealed on Hyperfilms (Amersham) by using the ECL
chemiluminescent substrate (GE Healthcare).
Ligand binding ELISA assay
Microtiter plates (96-well) were coated with 250 ng of in-
dicated mAbs in 0.1 M sodium carbonate buffer, pH = 9.6
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of bovine serum albumin in PBS (Gibco) for 2 h at 37°C.
The wells were then incubated with the indicated proteins
for 2 h at 37°C. Binding of CD85j-Fc fusion protein (R&D
System) to immobilized GST-tagged human S100A8
or S100A9 monomer proteins (Tebu-bio) was detected
by adding horseradish peroxydase-antihuman-Fc mAbs
(Jackson Immunoresearch). Binding of either S100A8
monomer, S100A9 monomer or S100A9 tetramer (Protei-
nia, SA) to immobilized CD85j-Fc protein was detected by
adding horseradish peroxydase-conjugated goat anti-GST
polyclonal antibody (GE Healthcare). For blocking experi-
ments, S100A8 or S100A9 proteins were added to the
CD85j-Fc-immobilized wells in the presence of varying
amounts of soluble CD85j-Fc or NKG2D-Fc (R&D Sys-
tem) protein. After a final wash step, a substrate reagent
containing tetramethylbenzidine and hydrogen peroxide
was added. Colours absorbance was measured at 570 nm
using a spectrophotometer.
Analysis of S100A8, S100A9 and S100A8/S100A9 surface
expressions
Uninfected or HIV-1-infected MDDC were stained with
either mouse anti-human S100A8 (2H2) or S100A9 (1C10)
mAbs followed with PE-conjugated donkey anti-mouse
secondary reagent (Jackson Immunoresearch). MDDC
were directly stained with PE-conjugated mouse anti-
human S100A8/S100A9 (27E10) mAb (Tebu-bio). After
washing, cells were resuspended in PBS and analysis was
performed on a FC500 instrument (Beckman Coulter).
Production of S100A9 proteins
S100A9 monomers were purchased from Tebu-bio.
S100A9 tetramer protein was produced by Protenia (Dr El
Yahyaoui, Ifrane, Morocco) by standard procedures. Briefly,
S100A9 (Calgranuline B) was cloned in pET3a vector and,
after verification of the insert, BL21(DE3) Origami E. coli
strain was transformed. Production of tetramer was tested
after strain lysis and protein purification was verified by
SDS-Page gel (Additional file 6: Figure S6). Proteins used
in the experiments were LPS free.
Analysis of intracellular cytokine production and CD107a
expression by NK cells
After incubation with 1 μg/mL of either S100A9 monomer
or tetramer for 4 hour, NK cells were overnight stimulated
or not by HLA class-I-devoid K562 cells. CD107a assay was
done as previously described [33]. After washing, cells were
resuspended in PBS and analysis was performed on a LSRII
instrument (BD Biosciences) on gated cells within the
lymphocyte population. Within the CD3-CD56 + CD16+
population, we noted the independent expression of
CD107a, TNF-α, IFN-γ for each sample following stimula-
tion. We used PECy5-anti-CD107a (BD Biosciences),FITC-anti-IFN-γ (Beckman Coulter) and PE-anti-TNF-α
(BD Biosciences) mAbs.
Analysis of HIV-1 replication
Replication of HIV-1 was detected by measuring intracel-
lular p24cbl by flow cytometry. After a formaldehyde/sap-
onin-based fixation/permeabilization (IntraPrep, Beckman
Coulter), HIV-1-infected MDDC or CD4+ T cells were
stained with PE-anti-p24 (KC57 RD1) mAbs (Beckman
Coulter) for 30 min. After washing, cells were resuspended
in PBS until flow cytometric analysis was performed.
Given that the CD4 antigen is down modulated after T cell
activation and/or infection [34], we used the CD3 expres-
sion to distinguish CD3 + CD4+ T cells and CD3-CD56+
NK cells in co-culture. Infection of CD3+ T cells and
MDDC with HIV-1 Bal strain was analysed in a LSRII in-
strument (Becton Dickinson). The presence of viral parti-
cles in the supernatant was determined by ELISA Test
(RETROtek p24 Antigen ELISA kit, ZeptoMetrix Corp.)
according to the manufacturers’ protocol.
Inhibition of HIV-1 replication assay
Infections of MDDC and CD4+ T cells were performed
with HIV-1 Bal strain at 10-2 moi. NK cells and infected tar-
get cells were co-cultured at a ratio E/T of 1:5 (20.103NK/
100.103MDDC or 20.103NK/100.103CD4+ T cell per well,
in a 96 well plate). CD4+ T cells were stimulated for 4 days
with Phytohaemagglutinin-L (PHA-L) at 1 μg/ml in the
presence of IL-2 at 100 U/ml prior the infection. HIV-1 in-
fection of cells was recorded after 7 and 10 days of co-
culture by measuring intracellular p24 by flow cytometry
and assessing the amount of p24 antigen in supernant by
ELISA test. When indicated, NK cells were stimulated or
not for 1 h by full-length recombinant GST-tagged human
S100A9 monomers (Tebu-bio) or by S100A9 tetramers
(Protenia, SA) at 1 μg/ml.
Role of the funding source
The French National Agency for AIDS and Hepatitis Re-
search (ANRS) funded this study (ANRS 9070 study). The
funder had no role in study design, data collection and ana-
lysis, decision to publish, or preparation of the manuscript.
Statistical analyses
Data was analysed by non-parametric (Mann–Whitney
test) and parametric tests (Student’s two-tailed paired
t-test). The results are expressed as the sample mean ± SE.Additional files
Additional file 1: Figure S1. S100A8 and S100A9 Gel Sequencing. (A)
Eluted proteins from the column were separated by electrophoresis in
non-reducing conditions and revealed by Coomassie blue staining. Lane
3, Seeblue® Plus2 Pre-Stained Standard, lanes 1–2, subsequent eluted
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CD85j-Fc-coupled gel. (B) Protein sequencing results are summarized:
S100A8/S100A9 (Band 01), S100A9 (Bands 02a and 02b) and S100A8
(Band 03) proteins.
Additional file 2: Figure S2. ELISA-based CD85j/S100A9 proteins
binding assay. CD85j-Fc coated on the wells of a microtiter plate was
incubated with increasing amounts of S100A9 monomer or tetramer
proteins.
Additional file 3: Figure S3. HIV-1 dose-dependent modulations of
S100A8, S100A9 and S100A8/S100A9 at the surface of MDDC. Statistical
analyses showing the spearman correlation between the frequency of
p24+ MDDC and the surface expression of S100A8
(A), S100A9 (B), or S100A8/S100A9 complex (C). MDDC were infected
with different multiplicity of HIV-1 infection and stained after 7 days of
culture. Each dot represents one flow cytometry analysis from a different
individual.
Additional file 4: Figure S4. Expression of S100A9 protein at the
surface of MDDC in response to productive or non-productive HIV-1
infection. (A) Cumulative results showing S100A9 and expression at the
surface of uninfected (Control Media), replicating (HIV-1 p24+) or not
(HIV-1 p24-) HIV-1-infected MDDC, 7 days of culture. (B) Expression
S100A9 on the surface of MDDC p24- in the context of a productive
(HIV-1, HIV-1ΔNef, or HIV-1ΔVpu) or a non-productive HIV-1 infection
(HIV-1ΔEnv VSV), compared to the condition of non-infection (Control
Media). Results are expressed as mean ± SE of percentage of MDDC
expressing S100A9 at the surface. Results of 6 independent experiments
are summarized. * p < 0.05.
Additional file 5: Figure S5. Quantification and analysis of the
purification of S100A9 tetramers by 12% SDS-PAGE. Lane 1: 0.25 μg BSA;
Lane 2: 0.5 μg BSA; Lane 3: 1 μg BSA; Lane 4: 2 μg BS; Lane 5: MM; Lane
6: 1 μL of eluted solution; Lane 7: 2 μL of eluted solution; Lane 8: 3 μL of
eluted solution.
Additional file 6: Figure S6. Increase in TNF α production.
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